Consumer Electronics company Symphony announced Q1FY26 results Revenue from Operations: Rs 251 crore compared to Rs 393 crore during Q1FY25, change -36%. EBITDA: Rs 26 crore compared to Rs 88 crore during Q1FY25, change -71%. EBITDA Margin: 10.2% for Q1FY26. PAT: Rs 42 crore compared to Rs 88 crore during Q1FY25, change -52%. Nrupesh Shah, Managing Director (Corporate Affairs), Symphony, said: Symphony Limited today announced its financial results for the quarter ending June 2025, reporting a 39% YoY decline in standalone revenue. This is primarily attributed to pronounced seasonal headwinds, further accentuated by a high base of the June 2024 quarter. Symphony delivered its second-highest June quarter (summer-season) standalone revenue on record and surpassed earlier second-best summer season, despite a shortened and rain-impacted summer-25, coupled with the early onset of monsoon. Standalone EBITDA margin declined by 11.7%, primarily due to product mix and YoY reduced operating leverage. GSK China continued its robust growth momentum, making strides towards becoming debt-free. During FY26 yearto-date, GSK China repaid Rs 27.9 crore towards its inter-company loan to Symphony India, reducing outstanding loan to Rs 26.1 crore from a peak of Rs 59.8 crore in May 2024. The trajectory is bolstered by intellectual property rights monetization and internal cash generation. IMPCO Mexico experienced subdued performance attributed to a milder summer, which moderated EBITDA margins due to YoY lower operating leverage. Symphony AU Australia posted its second consecutive quarter of year-on-year growth, driven by ongoing business transformation initiatives. Key levers fueling this momentum include an asset-light operating model, strategic product and market expansion, accelerated sales, and cost optimization. GSK China has successfully transferred technology know-how and nine intellectual property rights (IPRs) to IMPCO Mexico. The total transaction is valued at ~ Rs 44 crore, with the first tranche, amounting to around Rs 22 crore, already completed. The remaining balance is scheduled for completion in the September 2025 quarter. This move not only accelerates IMPCO Mexico’s product-led growth but also enhances prospects for IMPCO’s divestment / monetization. GSK China continues to retain a strong portfolio of products and IPRs, ensuring sustained innovation and future growth. Result PDF